G1 Therapeutics Inc at 38th Annual J.P Morgan Healthcare Conference Transcript
Okay. We'll go ahead and get started. I want to thank everyone for coming. This is the Tuesday morning of the 2020 JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Tessa Romero and Matt Bannon from the team. Our next presenting company is G1 Therapeutics. And speaking on behalf of the company, we have CEO, Mark Velleca. Mark?
Good morning. Thanks, Anupam, for the introduction. I appreciate the opportunity to share the G1 Therapeutics story with all of you here today in San Francisco. I'd also like to welcome those joining via webcast.
2020 is an important year for G1 as we prepare to file our first NDA for our lead program, trilaciclib. So our safe harbor statement. G1 is advancing 3 investigational therapies. Trilaciclib, rintodestrant and lerociclib. But it's trilaciclib that makes us unique from our peers in the oncology
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |